Thromboembolie avec des inhibiteurs de Janus Kinase (JAK) dans le cas de la Polyarthrite Rhumatoïde : Quel est le risque réel ?
Drug Safety 2018 Jul;41(7):645–53
Current data suggests that JAK inhibitors may increase the risk of thromboembolism and pulmonary thrombosis (PT) in RA.Two JAK inhibitors – baricitinib (BARI) and tofacitinib (TOF) – are considered effective treatments for RA, however, there are concerns about the thromboembolic risks associated with them. In August 2017, the summary of product characteristics for BARI was revised to include a warning of developing DVT and pulmonary embolism (PE), with recommendations that BARI should be used wi...